Logo image of LMNL

LIMINAL BIOSCIENCES INC (LMNL) Stock Fundamental Analysis

NASDAQ:LMNL - Nasdaq - CA53272L2021 - Common Stock - Currency: USD

8.5  +0.01 (+0.12%)

Fundamental Rating

2

Overall LMNL gets a fundamental rating of 2 out of 10. We evaluated LMNL against 563 industry peers in the Biotechnology industry. LMNL has a bad profitability rating. Also its financial health evaluation is rather negative. LMNL does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year LMNL was profitable.
In the past year LMNL has reported a negative cash flow from operations.
In multiple years LMNL reported negative net income over the last 5 years.
LMNL had a negative operating cash flow in each of the past 5 years.
LMNL Yearly Net Income VS EBIT VS OCF VS FCFLMNL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 -50M -100M -150M -200M

1.2 Ratios

LMNL has a Return On Assets of 1.46%. This is amongst the best in the industry. LMNL outperforms 93.73% of its industry peers.
Looking at the Return On Equity, with a value of 2.16%, LMNL belongs to the top of the industry, outperforming 93.73% of the companies in the same industry.
Industry RankSector Rank
ROA 1.46%
ROE 2.16%
ROIC N/A
ROA(3y)-29.63%
ROA(5y)-80.67%
ROE(3y)-159.64%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LMNL Yearly ROA, ROE, ROICLMNL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 200 -200 -400

1.3 Margins

With an excellent Profit Margin value of 94.11%, LMNL belongs to the best of the industry, outperforming 99.67% of the companies in the same industry.
The Operating Margin and Gross Margin are not available for LMNL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 94.11%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LMNL Yearly Profit, Operating, Gross MarginsLMNL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 2K -2K -4K -6K -8K

More info and screens

3

2. Health

2.1 Basic Checks

LMNL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LMNL remains at a similar level compared to 1 year ago.
The debt/assets ratio for LMNL has been reduced compared to a year ago.
LMNL Yearly Shares OutstandingLMNL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M
LMNL Yearly Total Debt VS Total AssetsLMNL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

LMNL has an Altman-Z score of -45.25. This is a bad value and indicates that LMNL is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of LMNL (-45.25) is worse than 95.71% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that LMNL is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.02, LMNL perfoms like the industry average, outperforming 41.09% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -45.25
ROIC/WACCN/A
WACC7.87%
LMNL Yearly LT Debt VS Equity VS FCFLMNL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M -100M

2.3 Liquidity

A Current Ratio of 2.78 indicates that LMNL has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.78, LMNL is doing worse than 74.75% of the companies in the same industry.
LMNL has a Quick Ratio of 2.78. This indicates that LMNL is financially healthy and has no problem in meeting its short term obligations.
LMNL has a worse Quick ratio (2.78) than 72.94% of its industry peers.
Industry RankSector Rank
Current Ratio 2.78
Quick Ratio 2.78
LMNL Yearly Current Assets VS Current LiabilitesLMNL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

LMNL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -99.10%.
Looking at the last year, LMNL shows a very negative growth in Revenue. The Revenue has decreased by -12.92% in the last year.
Measured over the past years, LMNL shows a very negative growth in Revenue. The Revenue has been decreasing by -59.99% on average per year.
EPS 1Y (TTM)-99.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-53.93%
Revenue 1Y (TTM)-12.92%
Revenue growth 3Y-56.58%
Revenue growth 5Y-59.99%
Sales Q2Q%-28.66%

3.2 Future

Based on estimates for the next years, LMNL will show a very negative growth in Earnings Per Share. The EPS will decrease by -230.98% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-907.27%
EPS Next 2Y-230.98%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LMNL Yearly Revenue VS EstimatesLMNL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
LMNL Yearly EPS VS EstimatesLMNL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 0 10 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 77.27 indicates a quite expensive valuation of LMNL.
93.89% of the companies in the same industry are more expensive than LMNL, based on the Price/Earnings ratio.
LMNL's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.99.
LMNL is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 77.27
Fwd PE N/A
LMNL Price Earnings VS Forward Price EarningsLMNL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LMNL Per share dataLMNL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

A cheap valuation may be justified as LMNL's earnings are expected to decrease with -230.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-230.98%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LMNL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIMINAL BIOSCIENCES INC

NASDAQ:LMNL (9/25/2023, 8:00:18 PM)

8.5

+0.01 (+0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2023-08-08/amc
Earnings (Next)11-07 2023-11-07/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap19.82M
Analysts43.33
Price Target7.65 (-10%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 77.27
Fwd PE N/A
P/S 55.26
P/FCF N/A
P/OCF N/A
P/B 1.27
P/tB 1.59
EV/EBITDA N/A
EPS(TTM)0.11
EY1.29%
EPS(NY)-8.96
Fwd EYN/A
FCF(TTM)-11.29
FCFYN/A
OCF(TTM)-11.29
OCFYN/A
SpS0.15
BVpS6.71
TBVpS5.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.46%
ROE 2.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 94.11%
GM N/A
FCFM N/A
ROA(3y)-29.63%
ROA(5y)-80.67%
ROE(3y)-159.64%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.29%
Cap/Sales 0.61%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.78
Quick Ratio 2.78
Altman-Z -45.25
F-Score4
WACC7.87%
ROIC/WACCN/A
Cap/Depr(3y)12.21%
Cap/Depr(5y)35.07%
Cap/Sales(3y)46.16%
Cap/Sales(5y)49.99%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-99.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-53.93%
EPS Next Y-907.27%
EPS Next 2Y-230.98%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-12.92%
Revenue growth 3Y-56.58%
Revenue growth 5Y-59.99%
Sales Q2Q%-28.66%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.94%
OCF growth 3YN/A
OCF growth 5YN/A